Tag Archives: Pediatric

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Pediatric leukemia 'super drug' could be developed in the coming years

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development. When a key protein responsible for leukemia, MLL, is stabilized, it slows the… Read More »

Study highlights role of EHRs in pediatric medication errors

Dive Brief: Prescribing medications for kids requires unique considerations such as lower body weight, which could lead even small errors to cause patient harm. Yet little is known about how EHR usability issues affect medication errors, a new Health Affairs study says. Raj Ratwani of MedStar Health’s National Center for Human Factors in Healthcare and other… Read More »